Clinical trials: Type 2 Diabetes (T2D)
Obesity, Overweight
Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and…
- Trial name
- NCT01601704
- Testing
- NB32, PBO, Weight Management Program
- Where
- 224 sites in United States
- Volunteers
- 8,910 people
- Sponsor
- Orexigen Therapeutics, Inc
Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone
The objective of this study is to evaluate the efficacy and safety of dual add-on therapy with Gemigliptin 50 mg and Dapagliflozin 10 mg added to Metformin compared to add-on therapy with Gemigliptin 50 mg in combination with…
- Trial name
- NCT04255238
- Testing
- Gemigliptin 50mg, Dapagliflozin 10mg
- Volunteers
- 468 people
- Sponsor
- LG Chem
Diabetes Mellitus Type 2
Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy
Primary objective of this study is to compare diabetes-related healthcare utilization and costs in patients initiating exenatide once weekly vs insulin glargine.
- Trial name
- NCT02843399
- Where
- United States
- Volunteers
- 15,498 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Plant-based Ingredient on Post Prandial Glucose in Type II Diabetes
Effects of a plant based ingredient on blood glucose in Type II diabetes patients.
- Trial name
- NCT02256332
- Testing
- Low dose plant based ingredient, High dose plant based ingredient, Reference food format
- Where
- 2 sites in India
- Volunteers
- 24 people
- Sponsor
- Unilever R&D
Diabetic Nephropathy
Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy
This trial is randomized, placebo-controlled, double blind, double dummy, multi-centre trial. Screening period (4 week) Double blind treatment period (16 weeks)
- Trial name
- NCT01726816
- Testing
- Probucol 250mg/day, Probucol 500mg/day
- Where
- 16 sites in South Korea
- Volunteers
- 126 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
Efficacy Study of the DIAMOND System to Treat Type 2 Diabetes Mellitus
The study purpose is to demonstrate the benefit of a simplified version of the DIAMOND System (A third Generation) in comparison to a sham treatment in terms of Glycemic control, measured as A1c, FBG and Post-Prandial Glucose…
- Trial name
- RUBY (NCT01529216)
- Testing
- DIAMOND System
- Where
- 2 sites in France, Netherlands
- Volunteers
- 2 people
- Sponsor
- MetaCure Limited
Type 2 Diabetes
Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin
This is a multicenter, randomized, double-blind, placebo- and active comparator-controlled phase 2/3 study of three dose levels of MBX-102 (200, 400, 600 mg) given orally to patients with type 2 diabetes receiving concomitant…
- Trial name
- NCT00353587
- Testing
- MBX-102, Actos
- Where
- 67 sites in United States, Argentina and 2 more
- Volunteers
- 396 people
- Sponsor
- Gilead Sciences
Diabetes Mellitus, Type 2
Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to investigate the success rate of a switch from insulin therapy to a metformin \& saxagliptin combination in patients with type 2 diabetes mellitus.
- Trial name
- NCT01206647
- Testing
- Metformin and Saxagliptin
- Where
- 7 sites in Germany
- Volunteers
- 120 people
- Sponsor
- ikfe-CRO GmbH
Type 2 Diabetes Mellitus
A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes
This will be a randomized, open label, parallel group, multicenter study. There will be two phases in the study. Phase 1 (Baseline to Week 24) will compare the efficacy and safety of regimens of basal insulin intensified with…
- Trial name
- NCT00467649
- Testing
- pramlintide acetate (Symlin), rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]), basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
- Where
- 37 sites in United States
- Volunteers
- 112 people
- Sponsor
- AstraZeneca
Normal Eyes of Subjects Without Diabetes Mellitus, Subjects With Diabetes Mellitus Type 2 Without Coexisting DPN
Repeatability of Static & Dynamic Composite Confocal Microscopy for Assessment of the Corneal Nerve Fiber Plexus in Early Diabetic Polyneuropathy
This prospective study was was divided into 2 parts and carried out at 2 sites in Germany. Part 1 assessed Repeatability in healthy, non-diabetic population (Group "control").
- Conditions
- Normal Eyes of Subjects Without Diabetes Mellitus, Subjects With Diabetes Mellitus Type 2 Without Coexisting DPN, Subjects With Diabetes Mellitus Type 2 With Coexisting Early to Moderate DPN
- Trial name
- NCT05326958
- Testing
- HRT RCM, HRT RCM-E
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Heidelberg Engineering GmbH
Type 2 Diabetes Mellitus
A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the effect of study drug known as LY3209590 compared to insulin glargine administered in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT04957914
- Testing
- Insulin Glargine, LY3209590
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Bioavailability of Technosphere® Insulin Versus Subcutaneous Regular Human Insulin in Type 2 Diabetes
The purpose of this study is to compare the kinetics and biodynamics of inhaled Technosphere Insulin with those of subcutaneous (SC) regular human insulin.
- Trial name
- NCT00511719
- Testing
- Technosphere Insulin, Actrapid
- Volunteers
- 13 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus Type 2
A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy
This randomized, open-label, parallel arm study will compare the safety, tolerability and effect on glycemic control of taspoglutide versus insulin glargine in insulin-naïve patients with type 2 diabetes mellitus inadequately…
- Trial name
- NCT01051011
- Testing
- insulin glargine, metformin, taspoglutide
- Where
- 56 sites in China, Hong Kong and 5 more
- Volunteers
- 370 people
- Sponsor
- Hoffmann-La Roche
Healthy Volunteers, Overweight
First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes
The purpose of this study is to investigate how safe, and how well tolerated, the new study drug NNC0480-0389 is when it is given together with semaglutide.
- Conditions
- Healthy Volunteers, Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04259801
- Testing
- NNC0480-0389, Semaglutide
- Where
- Netherlands
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type2 Diabetes, High Blood Sugar
Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus
This is a long term, single arm, open label study to evaluate the safety and efficacy of dapagliflozin as monotherapy or in combination therapy with other anti diabetic drug in Japanese subjects with type 2 diabetes mellitus who…
- Trial name
- NCT01294436
- Testing
- Dapagliflozin
- Where
- 38 sites in Japan
- Volunteers
- 728 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes
This trial is conducted in Japan. The aim of this trial is to investigate the efficacy and safety of NN5401 (insulin degludec/insulin aspart) with insulin glargine in subjects with type 2 diabetes in Japan.
- Trial name
- BOOST™ (NCT01272193)
- Testing
- insulin degludec/insulin aspart, insulin glargine
- Where
- 50 sites in Japan
- Volunteers
- 296 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
The Drug -Drug Interaction of SP2086 and Glyburide
The purpose of the study is to investigate the potential interaction between SP2086 and Glyburide after the singe and multiple oral doses treatment in healthy adult volunteers respectively.
- Trial name
- NCT02815787
- Testing
- SP2086, Glyburide
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
WelChol® With Metformin in Treating Patients With Type 2 Diabetes
The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to metformin alone or in combination with other anti-diabetic drugs.
- Trial name
- NCT00147719
- Testing
- Colesevelam hydrochloride
- Where
- 48 sites in United States, Mexico and 1 more
- Volunteers
- 300 people
- Sponsor
- Daiichi Sankyo
Type 2 Diabetes Mellitus
Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
- Trial name
- NCT05666128
- Testing
- HD-6277
- Where
- South Korea
- Volunteers
- 112 people
- Sponsor
- Hyundai Pharm
Type 2 Diabetes
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin
This study is a multicenter, randomized, double-blind (with open-label dose levels and active comparator), parallel-group, placebo- and active-controlled Phase 2 clinical trial aimed at evaluating the efficacy, safety…
- Trial name
- NCT07109700
- Testing
- HDM1005 1, HDM1005 2, HDM1005 3
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.